Drugs in R & D

, Volume 1, Issue 6, pp 463–469 | Cite as

Lipid-Altering Drugs in Development

  • Harold E. Bays
  • Carlos A. Dujovne
Section 2: Lipid Disorder Leading Article


Although currently available lipid lowering therapies are effective and well tolerated, the search continues for additional treatments with even better efficacy and tolerability profiles. As well as refinements to existing strategies (new HMG-CoA reductase inhibitors, fibrates and combination therapies) new avenues are being explored. These include inhibitors of enzymes other thanHMG-CoA reductase involved in cholesterol regulation and drugs which affect absorption of lipids from the gastrointestinal tract. In the case of the latter, it has been shown that the new antiobesity treatment orlistat can favourably affect the blood lipid profile. In line with an increasing emphasis on improving high density lipoprotein-cholesterol (HDL-C) levels, the potential therapeutic roles of niacin and drugs which inhibit enzymes involved in the metabolism of HDL-C are also being researched.


Adis International Limited Orlistat Cholesteryl Ester Transfer Protein Sibutramine Microsomal Triglyceride Transfer Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zeneca Pharmaceuticals. Zeneca accelerates Phase III studies of cholesterol-lowering superstatin [press Release]. Wilmington (DE): Zeneca Pharmaceuticals, 1999, Feb 15Google Scholar
  2. 2.
    Murakami S, Ohta Y, Asami Y, et al. The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow. Gen Pharmacol 1996; 27 (8): 1383–6PubMedCrossRefGoogle Scholar
  3. 3.
    Loirdighi N, Menard D, Delvin E, et al. Ontogeny and location of HMG-CoA reductase, ACAT, and MGAT in human small intestine. Am J Physiol 1997; 273 (1 Pt 1): G62–7PubMedGoogle Scholar
  4. 4.
    Aragane K, Kusunoki J, Kitamine T, et al. Effects of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion. Jpn J Pharmacol 1998; 76 (3): 309–12PubMedCrossRefGoogle Scholar
  5. 5.
    Vaccaro W, Amore C, Berger J, et al. Inhibitors of acyl CoA: cholesterol acyltransferase. J Med Chem 1996; 39 (8): 1704–19PubMedCrossRefGoogle Scholar
  6. 6.
    Umeda Y, Hirano T, Kako Y, et al. A selective inhibitor of intestinal ACAT, EAB309 suppresses both intestinal and hepatic cholesterol output and stimulates chylomicron removal. Life Sci 1998; 63 (13): PL187–95PubMedCrossRefGoogle Scholar
  7. 7.
    Lee HT, Roark WH, Picard JA, et al. Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates. Bioorg Med Chem Lett 1998; 8 (3): 289–94CrossRefGoogle Scholar
  8. 8.
    Tanaka A, Terasawa T, Hagihara H, et al. Synthesis, X-ray crystal structure, and biological activity of FR186054, a novel, potent, orally active inhibitor of acyl-CoA: cholesterol O-acyltransferase (ACAT) bearing a pyrazole ring. Bioorg Med Chem Lett 1998; 8 (1): 81–6PubMedCrossRefGoogle Scholar
  9. 9.
    Yasuhara M, Saito K, Kubota H, et al. Inhibitory effect of a new ureidophenol derivative T-2591 on LDL oxidation and ACAT activity. Biol Pharm Bull 1997; 20 (10): 1056–60PubMedCrossRefGoogle Scholar
  10. 10.
    Asami Y, Kondo Y, Murakami S, et al. The ACAT inhibitor HL-004 inhibits cholesterol absorption and lowers serum cholesterol in rats. Gen Pharmacol 1998; 31 (4): 593–6PubMedCrossRefGoogle Scholar
  11. 11.
    Kusunoki J, Aragane K, Kitamine T, et al. Effect of F-1394, a potent and selective inhibitor of acyl-CoA: cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells. Nippon Yakurigaku Zasshi 1997; 110 (6): 357–65PubMedCrossRefGoogle Scholar
  12. 12.
    Azuma Y, Kawasaki T, Ikemoto K, et al. Cholesterol-lowering effects of NTE-122, a novel acyl-CoA: cholesterol acyltrans-ferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. Jpn J Pharmacol 1998; 78 (3): 355–64PubMedCrossRefGoogle Scholar
  13. 13.
    Riddell D, Bright CP, Burton BJ, et al. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenyl-imidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol 1996; 52 (8): 1177–86PubMedCrossRefGoogle Scholar
  14. 14.
    Asami Y, Yamagishi I, Murakami S, et al. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits. Life Sci 1998; 62 (12): 1055–63PubMedCrossRefGoogle Scholar
  15. 15.
    Fukuda T, Kitada Y, Chen XM, et al. Two new monoterpene glycosides from ku-ding-cha. Inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT). Chem Pharm Bull (Tokyo) 1996; 44 (11): 2173–6CrossRefGoogle Scholar
  16. 16.
    Chiari A, Lovisolo P, Fogliatto G, et al. Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor. Pharmacol Res 1996; 33 (3): 181–9PubMedCrossRefGoogle Scholar
  17. 17.
    Tanaka A, Terasawa T, Hagihara H, et al. Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT). Part 1: identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N’-arylureas. Bioorg Med Chem 1998; 6 (1): 15–30PubMedCrossRefGoogle Scholar
  18. 18.
    Kwon BM, Kim MK, Lee SH, et al. Acyl-CoA: cholesterol acyltransferase inhibitors from Magnolia obovata. Planta Med 1997; 63 (6): 550–1PubMedCrossRefGoogle Scholar
  19. 19.
    Purchase TS, Essenburg AD, Hamelehle KL, et al. Inhibitors of acyl-CoA: cholesterol acyltransferase: novel trisubstituted ureas as hypocholesterolemic agents. Bioorg Med Chem 1997; 5 (4): 739–47PubMedCrossRefGoogle Scholar
  20. 20.
    Musanti R, Giorgini L, Lovisolo PP, et al. Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J Lipid Res 1996; 37 (1): 1–14PubMedGoogle Scholar
  21. 21.
    Kataoka K, Shiota T, Takeyasu T, et al. Potent inhibitors of acyl-CoA: cholesterol acyltransferase. 2. Structure-activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl) amides. J Med Chem 1996; 39 (6): 1262–70PubMedCrossRefGoogle Scholar
  22. 22.
    Sakuma Y, Hagihara H, Nagayoshi A, et al. Effects of FR145237, an acyl-CoA: cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats. Life Sci 1997; 60 (6): 351–6PubMedCrossRefGoogle Scholar
  23. 23.
    Murakami S, Yamagishi I, Asami Y, et al. Effect of the ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages. Cell Mol Biol (Noisy-le-grand) 1996; 42 (6): 865–72Google Scholar
  24. 24.
    van Greevenbroek MM, Robertus-Teunissen MG, Erkelens DW, et al. Participation of the microsomal triglyceride transfer protein in lipoprotein assembly in Caco-2 cells: interaction with saturated and unsaturated dietary fatty acids. J Lipid Res 1998; 39 (1): 173–85PubMedGoogle Scholar
  25. 25.
    Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A 1996; 93 (21): 11991–5PubMedCrossRefGoogle Scholar
  26. 26.
    Du EZ, Wang SL, Kayden HJ, et al. Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. J Lipid Res 1996; 37 (6): 1309–15Google Scholar
  27. 27.
    Rustaeus S, Stillemark P, Lindberg K, et al. The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem 1998; 273 (9): 5196–203PubMedCrossRefGoogle Scholar
  28. 28.
    Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282 (5389): 751–4PubMedCrossRefGoogle Scholar
  29. 29.
    Gordon DA, Jamil H, Gregg RE, et al. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem 1996; 271 (51): 33047–53PubMedCrossRefGoogle Scholar
  30. 30.
    Jamil H, Chu CH, Dickson Jr JK, et al. Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J Lipid Res 1998; 39 (7): 1448–54PubMedGoogle Scholar
  31. 31.
    Amin D, Rutledge RZ, Needle SN, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997; 281 (2): 746–52PubMedGoogle Scholar
  32. 32.
    Judge rules against FDA in Cholestin challenge. Reuters News Service, 1999 Feb 17Google Scholar
  33. 33.
    What’s in the pipeline. R & D Directions 1998 May: 211Google Scholar
  34. 34.
    Dujovne CA, Bays HE, Davidson MH, et al. Reduction of LDL-cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. In pressGoogle Scholar
  35. 35.
    Salisbury BG, Davis HR, Burner RE, et al. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption. SCH 48461. Atherosclerosis 1995; 115: 45–63PubMedCrossRefGoogle Scholar
  36. 36.
    Harris WS, Dujovne CA, Windsor SL, et al. Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol 1997; 30 (1): 55–60PubMedCrossRefGoogle Scholar
  37. 37.
    Cutler DL, Kosoglou T, Alton KB, et al. Effect of a high fat vs non-fat meal on the bioavailability of SCH 48461 [abstract]. Clin Pharmacol Ther 1995; 57: 173Google Scholar
  38. 38.
    Bergman M, Morales H, Mellars L, et al. The clinical development of a novel cholesterol absorption inhibitor [abstract]. Proceedings of the XII International Symposium on Drugs Affecting Lipid Metabolism; 1995 Nov 7–10: Houston (TX). Houston (TX): Baylor College of Medicine, 1995: 5Google Scholar
  39. 39.
    Cutler DL, Kosoglou T, Alton KB, et al. Effect SCH 48461 on oral cholesterol absorption [abstract]. Clin Pharmcol Ther 1996; 59: 194CrossRefGoogle Scholar
  40. 40.
    Ichihashi T, Izawa M, Miyata K, et al. Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998; 284 (1): 43–50PubMedGoogle Scholar
  41. 41.
    Higaki J, Hara S, Takasu N, et al. Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18 (8): 1304–11PubMedCrossRefGoogle Scholar
  42. 42.
    Yamaguchi T, Nakajima Y, Mizobuchi M, et al. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs. Arzneimittelf Forschung 1998; 48 (10): 995–1006Google Scholar
  43. 43.
    Sjostrom L, Rissanen A, Andersen T, European Multicentre Orlistat Study Group, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352 (9123): 167–72PubMedCrossRefGoogle Scholar
  44. 44.
    Davidson MH, Hauptman J, DiGirolamo JP, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281 (3): 235–42PubMedCrossRefGoogle Scholar
  45. 45.
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21 (8): 1288–94PubMedCrossRefGoogle Scholar
  46. 46.
    Bray GA, Blackburn GL, Ferguson JM, et al. Sitbutramine produces dose-related weight loss. Obes Res 1999; 7 (2): 189–98PubMedGoogle Scholar
  47. 47.
    Kwiterovich Jr PO. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82 (9A): 13Q–21QPubMedCrossRefGoogle Scholar
  48. 48.
    Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol 1996; 78 (5): 572–5PubMedCrossRefGoogle Scholar
  49. 49.
    Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111 (3): 253–5PubMedGoogle Scholar
  50. 50.
    Morgan J M, Capuzzi DM, Guyton JR. Anew extended-release niacin (Niaspan): efficacy, tolerability, and safety in hyper-cholesterolemic patients [discussion no. 39U-41U]. Am J Cardiol 1998; 82 (12A): 29U–34UPubMedCrossRefGoogle Scholar
  51. 51.
    Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study [discussion no. 85U-86U]. Am J Cardiol 1998; 82 (12A): 74U–81UPubMedCrossRefGoogle Scholar
  52. 52.
    Tsutsumi K, Inoue Y, Hagi A, et al. The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity. Metabolism 1997; 46 (3): 257–60PubMedCrossRefGoogle Scholar
  53. 53.
    Bruce C. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998; 18: 297–330PubMedCrossRefGoogle Scholar
  54. 54.
    Hegde VR, Dai P, Patel M, et al. A depsidpeptide fungal metabolite inhibitor of cholesterol ester transfer protein. Bioorg Med Chem Lett 1998; 8 (11): 1277–80PubMedCrossRefGoogle Scholar
  55. 55.
    Cho KH, Lee JY, Choi MS, et al. A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim Biophys Acta 1998; 1391 (2): 133–44PubMedCrossRefGoogle Scholar
  56. 56.
    Bisgaier CL, Essenburg AD, Barnett BC, et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor [published erratum appears in J Lipid Res 1998; 39 (6): 1317]. J Lipid Res 1998; 39 (1): 17–30PubMedGoogle Scholar
  57. 57.
    KOS Pharmaceuticals. In the Future. KOS January 1999 Annual Report. Miami (FL): KOS Pharmaceuticals, 1999: 10Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Harold E. Bays
    • 1
  • Carlos A. Dujovne
    • 2
  1. 1.Louisville Metabolic and Atherosclerosis Research CenterNortons Audubon HospitalLouisvilleUSA
  2. 2.Mid-Continent Clinical Trials - Radiant Research, Lipid, Heart Disease, Stroke and Weight Control Metabolic Diseases ClinicsKansas Foundation for Clinical PharmacologyOverland ParkUSA

Personalised recommendations